1210838-82-6

Basic information

• Product Name: 5-bromo-3-ethynylpyridin-2-amine
• Synonyms: 5-bromo-3-ethynylpyridin-2-amine
• CAS NO: 1210838-82-6
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.032
• Mol File: 1210838-82-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-bromo-3-ethynylpyridin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-ethynylpyridin-2-amine(1210838-82-6)
• EPA Substance Registry System: 5-bromo-3-ethynylpyridin-2-amine(1210838-82-6)

Safety Data

• Hazardous Substances Data: 1210838-82-6(Hazardous Substances Data)

Usage

General Description

5-bromo-3-ethynylpyridin-2-amine is a chemical compound with the molecular formula C7H5BrN2. It is a derivative of pyridine and contains a bromine atom and an ethynyl group. 5-bromo-3-ethynylpyridin-2-amine is commonly used in the field of organic synthesis, particularly in the development of pharmaceuticals and agrochemicals. Its unique structure makes it a valuable building block for creating complex molecules with potential biological activity. Additionally, 5-bromo-3-ethynylpyridin-2-amine may also find applications in chemical research and as a reagent in laboratory experiments. Overall, it is a versatile chemical with diverse potential uses in various scientific and industrial applications.

Upstream product

• 1262985-25-0 4-(2-amino-5-bromopyridin-3-yl)-2-methylbut-3-yn-2-ol 
• 381233-96-1 2-amino-3-iodo-5-bromopyridine 
• 905966-34-9 5-bromo-3-(2-(trimethylsilyl)ethynyl)pyridine-2-amine 
• 115-19-5 2-methyl-but-3-yn-2-ol 

Downstream Products

• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 1617499-00-9 3-(1-isopropyltriazol-4-yl)-5-[3-(morpholinomethyl)phenyl]pyridin-2-amine 
• 1617499-01-0 [3-[6-amino-5-(1-isopropyltriazol-4-yl)-3-pyridyl]phenyl]morpholinomethanone 
• 1617499-02-1 [3-[6-amino-5-(1-isopropyltriazol-4-yl)-3-pyridyl]-5-chlorophenyl]morpholinomethanone 
• 1617499-03-2 5-[3-chloro-5-(morpholinomethyl)phenyl]-3-(1-isopropyltriazol-4-yl)pyridin-2-amine 
• 1617499-04-3 [4-[6-amino-5-(1-isopropyltriazol-4-yl)-3-pyridyl]phenyl]morpholinomethanone 
• 1617499-06-5 2-[4-[6-amino-5-(1-isopropyltriazol-4-yl)-3-pyridyl]phenyl]-1-morpholinoethanone 
• 1617499-19-0 4-(6-amino-5-(1-isopropyl-1H-1,2,3-triazol-4-yl)pyridin-3-yl)-2-methoxybenzoic acid 
• 1617499-20-3 (5-(6-amino-5-(1-isopropyl-1H-1,2,3-triazol-4-yl)pyridin-3-yl)-2-fluorophenyl)(morpholino)methanone 
• 1617499-21-4 4-(6-amino-5-(1-isopropyl-1H-1,2,3-triazol-4-yl)pyridin-3-yl)-2-methylbenzoic acid 
• 1617498-88-0 3-(1-isopropyl-1H-[1,2,3]triazol-4-yl)-5-(4-morpholin-4-ylmethyl-phenyl)-pyridin-2-ylamine 
• 1617498-89-1 3-(1-isopropyl-1H-[1,2,3]triazol-4-yl)-5-(4-morpholin-4-ylphenyl)pyridin-2-ylamine 
• 1617498-90-4 3-(1-isopropyl-1H-[1,2,3]triazol-4-yl)-5-[4-(2-morpholin-4-ylethyl)phenyl]pyridin-2-ylamine 
• 1617498-91-5 5-(3-fluoro-4-(morpholinomethyl)phenyl)-3-(1-isopropyl-1H-1,2,3-triazol-4-yl)pyridin-2-ylamine 

Relevant articles and documents

Discovery and Toxicological Profiling of Aminopyridines as Orally Bioavailable Selective Inhibitors of PI3-Kinase γ

Using a novel physiologically relevant in vitro human whole blood neutrophil shape change assay, an aminopyrazine series of selective PI3Kγinhibitors was identified and prioritized for further optimization. Severe solubility limitations associated with the series leading to low oral bioavailability and poor exposures, especially at higher doses, were overcome by moving to an aminopyridine core. Compound 33, with the optimal balance of on-target activity, selectivity, and pharmacokinetic parameters, progressed into in vivo studies and demonstrated good efficacy (10 mg/kg) in a rat model of airway inflammation. Sufficient exposures were achieved at high doses to support toxicological studies, where unexpected inflammatory cell infiltrates in cardiovascular tissue prevented further compound development.

AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.